SiBone (NASDAQ:SIBN – Get Free Report) CEO Laura Francis sold 38,006 shares of the stock in a transaction on Monday, October 12th. The shares were sold at an average price of $20.05, for a total transaction of $762,020.30. Following the transaction, the chief executive officer directly owned 379,256 shares in the company, valued at approximately $7,604,082.80. This represents a 9.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Laura Francis also recently made the following trade(s):
- On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The stock was sold at an average price of $20.12, for a total transaction of $522,556.64.
- On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total transaction of $78,538.46.
- On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.
SiBone Stock Performance
SiBone stock opened at $19.68 on Friday. The firm has a fifty day simple moving average of $18.97 and a two-hundred day simple moving average of $16.55. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. SiBone has a twelve month low of $11.48 and a twelve month high of $21.89. The company has a market capitalization of $872.81 million, a PE ratio of -57.88 and a beta of 0.66.
SiBone (NASDAQ:SIBN – Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.06. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. The firm had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. Research analysts expect that SiBone will post -0.40 EPS for the current year.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. UBS Group raised their price target on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Weiss Ratings upgraded SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Truist Financial boosted their price objective on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, TD Cowen increased their price objective on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $24.50.
View Our Latest Analysis on SiBone
Institutional Investors Weigh In On SiBone
A number of large investors have recently added to or reduced their stakes in SIBN. Versant Capital Management Inc increased its position in shares of SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares during the period. D.A. Davidson & CO. raised its stake in shares of SiBone by 5.7% during the first quarter. D.A. Davidson & CO. now owns 36,882 shares of the company’s stock valued at $466,000 after acquiring an additional 1,991 shares during the last quarter. Diversified Trust Co boosted its holdings in shares of SiBone by 10.8% during the first quarter. Diversified Trust Co now owns 24,335 shares of the company’s stock worth $307,000 after purchasing an additional 2,375 shares during the period. State of Wyoming boosted its holdings in shares of SiBone by 70.8% during the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock worth $137,000 after purchasing an additional 4,490 shares during the period. Finally, Quantinno Capital Management LP boosted its holdings in shares of SiBone by 58.2% during the first quarter. Quantinno Capital Management LP now owns 29,475 shares of the company’s stock worth $372,000 after purchasing an additional 10,848 shares during the period. Institutional investors own 98.11% of the company’s stock.
About SiBone
SI-BONE, Inc is a medical device company focused on developing and commercializing products for the surgical treatment of disorders affecting the sacroiliac joint, which connects the spine to the pelvis. The company’s technology is intended to support minimally invasive procedures for patients with sacroiliac joint dysfunction and related conditions.
Its product portfolio includes the iFuse Implant System, a family of triangular titanium implants designed to stabilize and fuse the sacroiliac joint.
Further Reading
- Five stocks we like better than SiBone
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
